期刊
CANCER LETTERS
卷 352, 期 1, 页码 28-35出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2013.08.026
关键词
Personalized medicine; Circulating tumor cell; Chemotherapy; Drug resistance
类别
资金
- National Institutes of Health [CA143876]
- National Science Foundation Graduate Research Fellowship [DGE-0707428, DGE-1144153]
Personalized medicine holds great promise for cancer treatment, with the potential to address challenges associated with drug sensitivity and interpatient variability. Circulating tumor cells (CTC) can be useful for screening cancer drugs as they may reflect the severity and heterogeneity of primary tumors. Here we present a platform for rapidly evaluating individualized drug susceptibility. Treatment efficacy is evaluated directly in blood, employing a relevant environment for drug administration, and assessed by comparison of CTC counts in treated and control samples. Multiple drugs at varying concentrations are evaluated simultaneously to predict an appropriate therapy for individual patients. (C) 2013 The Authors. Published by Elsevier Ireland Ltd.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据